-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MiNK Therapeutics (NASDAQ:INKT) Shares Down 0.4%
MiNK Therapeutics (NASDAQ:INKT) Shares Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 169,116 shares. The stock had previously closed at $2.52.
Analysts Set New Price Targets
Separately, HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research note on Wednesday, August 10th. They issued a "buy" rating and a $7.00 price target for the company.
Get MiNK Therapeutics alerts:MiNK Therapeutics Price Performance
The business's 50 day moving average is $2.34 and its 200 day moving average is $2.02. The stock has a market cap of $84.80 million, a price-to-earnings ratio of -3.22 and a beta of -0.63.
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. As a group, analysts forecast that MiNK Therapeutics, Inc. will post -0.84 earnings per share for the current year.Hedge Funds Weigh In On MiNK Therapeutics
A hedge fund recently bought a new stake in MiNK Therapeutics stock. First Republic Investment Management Inc. bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 169,116 shares. The stock had previously closed at $2.52.
明克治疗公司(纳斯达克代码:iNKT-GET Rating)周三股价下跌0.4%,盘中一度跌至2.50美元,最新报2.51美元。午盘,约有7,858股股票易手,较169,116股的日均成交量下降95%。此前该股收盘价为2.52美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research note on Wednesday, August 10th. They issued a "buy" rating and a $7.00 price target for the company.
另外,HC Wainwright在8月10日星期三的一份研究报告中启动了对水貂治疗公司股票的报道。他们对该公司的评级为“买入”,目标价为7美元。
MiNK Therapeutics Price Performance
水貂治疗公司的价格表现
The business's 50 day moving average is $2.34 and its 200 day moving average is $2.02. The stock has a market cap of $84.80 million, a price-to-earnings ratio of -3.22 and a beta of -0.63.
该业务的50日移动均线切入位在2.34美元,200日移动均线切入位在2.02美元。该股市值为8480万美元,市盈率为-3.22倍,贝塔系数为-0.63倍。
Hedge Funds Weigh In On MiNK Therapeutics
对冲基金入股水貂治疗公司
A hedge fund recently bought a new stake in MiNK Therapeutics stock. First Republic Investment Management Inc. bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors.
一家对冲基金最近买入了水貂治疗公司的新股。根据第一共和投资管理公司在第三季度购买了水貂治疗公司(纳斯达克:iNKT-GET评级)股票的新头寸,该公司在最近提交给美国证券交易委员会(美国证券交易委员会)的文件中称。该基金购买了81,500股该公司股票,价值约172,000美元。截至最近一个季度末,First Republic投资管理公司拥有水貂治疗公司约0.24%的股份。该股目前由机构投资者持有1.07%的股份。
About MiNK Therapeutics
关于水貂治疗公司
(Get Rating)
(获取评级)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治疗公司是一家临床阶段的生物制药公司,致力于同种异体、现成、不变的自然杀伤T(INKT)细胞疗法的发现、开发和商业化,以治疗癌症和其他免疫介导性疾病。它的候选产品是AGENT-797,这是一种现成的同种异体药物,用于iNKT细胞治疗和治疗各种骨髓瘤疾病,目前处于第一阶段临床试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
- 免费获取StockNews.com关于水貂治疗的研究报告(INKT)
- 美联储轴心的问题不是是否,而是何时,这是为什么
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利好的3个股息之王
- 机构抛售Toll Brothers股票的涨势
- 低贝塔,高产量的坎贝尔汤公司很好
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对水貂治疗和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧